Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Cantor Fitzgerald
Teva
Covington
Boehringer Ingelheim

Generated: July 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Applied Research Systems ARS Holding, N v. v. Cell Genesys, Inc. (D. Mass. 2004)

Try a free trialSee Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Applied Research Systems ARS Holding, N v. v. Cell Genesys, Inc.
The small molecule drug covered by the patents cited in this case is ➤ Sign Up .
Biologic Drugs cited in Applied Research Systems ARS Holding, N v. v. Cell Genesys, Inc.
The biologic drug covered by the patents cited in this case is ➤ Sign Up .

Details for Applied Research Systems ARS Holding, N v. v. Cell Genesys, Inc. (D. Mass. 2004)

Date Filed Document No. Description Snippet Link To Document
2006-03-16 101 Exhibit A, Part I produced? 3 (Marked, Exhibit 2664, U.S. Patent 4 A. No. 4 5,240,832.) 5 Q. Prior to the time that you arrived…detect the 6 you Exhibit 2084, which is U.S. Patent 5,240,832; is 7 presence of the protein “l“SI-l beta…Right. But the patent application was in 11 Q. When did you start preparing your patent 11 preparation…product? l 3 neophyte in the area of patent sti§)rnissionf a patent 3 A. Uitimate§y. In a commercial sense… no issued patent 8 Q. Weii, there wouldn't be a likelihood of 9 Q. Was there a patent application External link to document
2006-03-23 103 Opposition to Motion only recently learned of U.S. Patent No. 5,240,832 (“the ‘832 patent”) or of Ms. Kelton’s co-inventorship…experiments reflected in the ‘071 patent” all involved TSH. See, e.g., ‘071 patent at col. 13, lines 22-25 (“…in the experiments reported in the patent. See, e.g., ‘071 patent at col. 13, lines 58-61 (“In this example…the ‘832 patent. (Exhibit D to Nielsen Decl.) And CGI, not ARS, introduced the ‘832 patent as an exhibit…inequitable conduct during the prosecution of the ‘071 patent. As explained in ARS’s motion to dismiss (filed External link to document
2006-08-03 122 Response art to ARS (but not CGI)) and U.S. Patent 5,464,’764 and U.S. Patent 5,50l,967 each of which anticipates…applicant to a patent shall authorize the Director to issue such patent on the filing in the Patent and Tradernarl…party cannot present a claim patentable to it that interferes with a patentable claim of the opposing party… Board of Patent Appeals and lnterferences shall . . . determine priority and patentability of invention… a facially invalid patent The Board, by resolving both priority and patentability, when these questions External link to document
2006-10-02 126 Memorandum of Law U.S. Patent 5,240,832 and Scott Chappel's testimony with respect to the same. rl`his patent, like… modify a cell line to express THSB. U.S. Patent 5,240,832 (Ex. C to Kelber Dec.) recites “The expression…testified that his prior art teaching in U.S. Patent 5,240,832 reflects the fact that use of a selectable…subject matter claimed in ARS’s ‘071 patent Which stands patentable to ARS over prior art teachings of …directed to the “same patentable invention as claims 3, 37 and 46 of ARS’s ‘071 patent.” Decision, page l32 External link to document
2006-10-02 127 Declaration U.S. Patent 5,024,939. 4. Attached hereto as Exhibit C is a true and correct copy ofU.S. Patent 5,240,832…(Tlsty Expert Report-Part 2)# (3) Exhibit B (US Patent '939)# (4) Exhibit C (US Paten '832)#…CGI and a claim of ARS not found by the Board of Patent Appeais and Interferences in Interference 105,§ External link to document
Date Filed Document No. Description Snippet Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Fish and Richardson
Citi
Chubb
Daiichi Sankyo
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.